Genetic insights into the association between inflammatory bowel disease and Alzheimer's disease

Lu Zeng[1], Charles C. White[1], David A. Bennett[2], Hans-Ulrich Klein[1], Philip L. De Jager[1*]

[1]Center for Translational and Computational Neuroimmunology, Department of Neurology and the Taub Institute for Research on Alzheimer's disease and the Aging brain, Columbia University Irving Medical Center, New York, NY, USA.

[2]Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.

Abstract

Background

Myeloid cells, including monocytes, macrophages, microglia, dendritic cells and neutrophils are a part of innate immunity, playing a major role in orchestrating innate and adaptive immune responses. Microglia are the resident myeloid cells of the central nervous system, and many Alzheimer's disease (AD) risk loci are found in or near genes that are highly or sometimes uniquely expressed in myeloid cells. Similarly, inflammatory bowel disease (IBD) loci are also enriched for genes expressed by myeloid cells. However, the extent to which there is overlap between the effects of AD and IBD susceptibility loci in myeloid cells remains poorly described, and the substantial IBD genetic maps may help to accelerate AD research.

Methods

Here, we leveraged summary statistics from large-scale genome-wide association studies (GWAS) to investigate the causal effect of IBD (including ulcerative colitis and Crohn's disease) variants on AD and AD endophenotypes. Microglia and monocyte expression Quantitative Trait Locus (eQTLs) were used to examine the functional consequences of IBD and AD risk variants enrichment in two different myeloid cell subtypes.

Results

Our results showed that, while *PTK2B* is implicated in both diseases and both sets of risk loci are enriched for myeloid genes, AD and IBD susceptibility loci largely implicate distinct sets of genes and pathways. AD loci are significantly more enriched for microglial eQTLs than IBD. We also found that genetically determined IBD is associated with a lower risk of AD, which may driven by a negative effect on the accumulation of neurofibrillary tangles (beta=-1.04, p=0.013). In addition, IBD displayed a significant positive genetic correlation with psychiatric disorders and multiple sclerosis, while AD showed a significant positive genetic correlation with amyotrophic lateral sclerosis.

Conclusion

To our knowledge, this is the first study to systematically contrast the genetic association between IBD and AD, our findings highlight a possible genetically protective effect of IBD on AD even if the majority of effects on myeloid cell gene expression by the two sets of disease variants are distinct. Thus, IBD myeloid studies may not help to accelerate AD functional studies, but our observation reinforces the role of myeloid cells in the accumulation of tau proteinopathy and provides a new avenue for discovering a protective factor.

Keywords: Inflammatory bowel disease, Alzheimer's disease, AD endophenotypes, GWAS, eQTL, Mendelian randomization, PheWAS

Background

Myeloid cells (i.e., monocytes, macrophages, microglia, dendritic cells and neutrophils), are an important component of the innate immune system and also play critical roles in tissue development, homeostasis, disease, and repair. Their regulatory architecture is gradually emerging (1, 2) and includes a number of different transcriptional programs, many of which are specialized for the tissue context in which a given myeloid cell finds itself. Dysfunction in the immunoregulatory roles of these cells may play a part in the pathogenesis of a subset to patients with inflammatory bowel disease (IBD). IBD, including its two major subtypes of ulcerative colitis (UC) and Crohn's disease (CD), is a chronic gastrointestinal inflammatory disease whose etiology remains poorly understood and leads to recurrent attacks of acute inflammation over more chronic changes (3). Different bone marrow-derived macrophages found in the intestinal epithelium and perhaps those in the enteric nervous system contribute to these acute and chronic inflammatory changes (4). By contrast, microglia, the resident myeloid cells in the central nervous system (CNS), arise from primitive yolk-sac emigrants that infiltrate the developing neuroectoderm that will differentiate into the CNS (5). Proliferation and activation of microglia in the human brain, concentrated around amyloid-beta (Aβ), neuritic plaques and neurofibrillary tangles (NFTs), is a prominent feature of Alzheimer's disease (AD) pathology (6). AD is the most common aging-related neurodegenerative disease and is the most common cause of dementia (7), and the majority of AD susceptibility loci contain genes expressed by microglia and monocytes (6, 8).Previous epidemiologic studies have reported that patients with IBD had a more than two-fold increase in the risk of developing dementia (9). What's more, dementia was diagnosed around 7 years earlier in people with IBD than in those without (10). However, more

robust evidence is needed to understand whether IBD and AD (instead of the broader diagnostic grouping of "dementia") are truly linked.

Here, we leveraged existing IBD and AD genome-wide association studies (GWAS), and microglial and monocyte expression Quantitative Trait Locus (eQTL) datasets to examine the extent to which functional consequences of IBD and AD risk variants may be shared or distinct. We investigated the genetic effect of IBD on AD and AD endophenotypes, and the genetic correlation among IBD, AD and other disease traits. Our results indicate that i) overall, IBD loci are different from AD loci, ii) while both sets of disease genes are enriched in monocytes, AD risk variants are more significantly enriched in microglia eQTLs than IBD, iii) Genetically determined IBD is associated with lower odds of AD and fewer neurofibrillary tangles (NFTs), iv) IBD showed a significant positive genetic correlation with psychiatric disorders and multiple sclerosis (MS), while AD showed a significant positive genetic correlation with amyotrophic lateral sclerosis (ALS), v) *PTK2B* may play an important role in both IBD and AD pathologies.

Materials and methods

IBD and AD variants collection

A recent study reported a combination of 241 SNPs with the smallest p-value in fifteen studies associated with IBD/UC/CD (11). We extracted the GWAS summary statistics (e.g., effect allele, effect size and p-value) from the study, and the NHGRI-EBI GWAS Catalog (https://www.ebi.ac.uk/gwas/); p-values smaller than 5×10^{-8} were retained for the following analyses, resulting in 228 IBD risk variants (Supplementary Table S1).

For AD variants, we downloaded summary statistics from a recent large GWAS (12), and extracted the variants' genotype information from 1000 Genome Project Utah Residents from north and West Europe (CEU) population. R cor (method=complete.obs) was used to calculate the correlation coefficients of the SNP matrix. For ld-linked variants (correlation coefficient>0.5), we measured their GWAS p-value and variants with the smallest p-value in each ld-block were kept for our analyses. No ld-linked variants with $p \leq 5\times10^{-8}$ were kept, resulting in 38 AD risk variants (Supplementary Table S2).

LD proxy calculation

The LDproxy Tool (https://analysistools.cancer.gov/LDlink/?tab=ldproxy) was used to calculate the linking correlated alleles of the 228 IBD variants and 38 AD variants. Using CEU population with ±500Mb window, only SNPs with R^2>=0.8 were kept for the following analyses, resulting in 7,875 IBD proxies and 894 AD proxies.

AD endophenotypes

GWAS summary statistics of AD endophenotypes were generated from ~1,300 genotyped ROSMAP participants, including amyloid, tangles, neuritic plaque burden, NFTs, cognitive decline and residual cognition adjusted by TDP pathology. We then filtered SNPs by using p-value<0.05.

For ten AD endophenotypes used in omnibus test and Phenome-wide association studies (PheWAS) analysis, which were AD pathologies measurement from 2,409 ROSMAP participants (details can be seen in Supplementary Table S3). For instance, cogng_demog_slope,

is the random slope of global cognition that estimated person-specific rate of change in the global cognition variable over time. It comes from a linear mixed effects model with global cognition as the longitudinal outcome. The model controls for age at baseline, sex, and years of education. amyloid_sqrt is the amyloid beta protein identified by molecularly-specific immunohistochemistry and quantified by image analysis. Value is percent area of cortex occupied by amyloid beta. Mean of amyloid beta score in 8 regions (https://www.radc.rush.edu/documentation.htm). For these 2,409 ROSMAP participants, their age at death ranged from 66yrs to 108yrs, with an average of 89.5yrs (SD=±6.53), among them 718 were male, and 1,691 female.

eQTL data

Monocyte cis-eQTL was downloaded from EMBL-EBI eQTL catalogue (https://www.ebi.ac.uk/eqtl/) (13), which aims to provide uniformly processed gene expression from all available public studies on human. The monocyte RNA-seq data was originally from BLUEPRINT study (https://www.blueprint-epigenome.eu/) (14), based on 197 European individuals, generated from whole blood. More details can be found at https://www.ebi.ac.uk/eqtl/Methods/.

Microglia single-nucleus RNA sequencing data was generated from the dorsolateral prefrontal cortex (DLPFC) of 424 ROSMAP (the Religious Order Study and the Rush Memory Aging Project). Both studies are harmonized and include older individuals tested annually all of who agreed to brain donation. They were approved by an Institutional Review Board of Rush University Medical Center. All participants signed informed and repository consents, and an

Anatomical Gift Act. Matrix eQTL (15) version 2.3 method was then used to identify cis-eQTLs with 1 MB of the transcription start site of each measure gene. More details can be found in our recent work (16). In this study, we only kept the eQTL-eGene pairs with p-value<0.05, including, and 263,263 microglia eQTL-eGene pairs.

Permutation test

Permutation analyses were carried out to test the significant of IBD/AD risk variants to be a microglia/monocyte eQTL, we randomly selected 38 and 228 variants from total 1000 Genome Project Utah Residents from north and West Europe (CEU) population array (13,601,136 SNPs) for 10,000 times, and checked how many of them were associated with gene expression regulation. Empirical p-value was then calculated to test the significance between permutation results and our analysis.

Omnibus test

PLINK/1.9 –score (17) was used to calculate the polygenic risk score (PRS) of 228 IBD risk on 2,409 ROSMAP donors. We then applied a generalized linear regression model using the R "glm" function to conduct the association test between the impact of IBD risk on ten AD endophenotypes (details can be seen in Supplementary Table S3). Adjusting for the covariates of age at death, sex and education years.

PheWAS analysis

Phenome-wide association studies (PheWAS) was further used to test the associations between 228 IBD risk variants (exposure) and ten AD endophenotypes (outcome), using the R PheWAS

package (18), adjusting for age at death, sex and education years. We used a linear regression model giving the numeric phenotype outcomes. We established significance using an FDR corrected *P*-value, accounting for ten AD endophenotypes.

Mendelian randomization

We performed Generalized Summary-data-based Mendelian Randomization (GSMR) (19) analyses between IBD (exposure) and AD (outcome) traits of interest using GWAS summary statistics, implemented in GCTA software (v1.93.1f beta). The instrumental variables were selected by a clumping procedure internal to the GSMR software with parameters: --gwas-thresh 5×10^{-8} --clump-r2 0.01. The HEIDI-outlier test was applied to test for horizontal pleiotropy ($P_{HEIDI} < 0.01$). For comparison, we performed two-sample MR analysis (2SMR) with the inverse-variance-weighted regression model and Egger regression model, implemented via the TwoSampleMR R package (20), using the instrumental variables selected by GSMR.

LD score regression (LDSC)

LDSC (21) bivariate genetic correlations attribute to genome-wide SNPs (r_g) were estimated with eleven human disease traits from published GWASs, including three IBD associated traits (IBD, UC and CD) (11), three neurodegenerative disorders: AD (12, 22), ALS (23) and Parkinson's disease (PD) (24), another inflammatory diseases, multiple sclerosis (MS) (25) and a metabolic disease type 2 diabetes (T2D) (26) and three psychiatric disorders: bipolar disorder (BD) (27), major depressive disorder (MDD) (28) and schizophrenia (SCZ) (29). Adjusting for the number of traits tested, the FDR *P*-value threshold (FDR<=0.05) was used to define significant genetic correlations.

Results

IBD risk loci are different from AD risk loci

To understand the functional consequences and potential interactions of IBD and AD susceptibility loci, we compiled a list of 228 IBD risk variants (meeting a threshold of genome-wide significance, $p \leq 5 \times 10^{-8}$) reported from a recent study (11) and 38 AD risk variants which meet the same threshold (Ncases=21,982; Ncontrols=41,944) (12) (Supplementary Table S1 & S2) (Figure 1A). We next investigated whether there was any overlap between the two lists of loci, and our results showed that there was no direct overlap between the two sets of top SNPs (Figure 1B). However, the top marker may not be the causal variant, and we therefore evaluated all SNPs that were in strong (R^2>=0.8) linkage disequilibrium (LD) with the top SNP in each locus using LDproxy (https://analysistools.cancer.gov/Ldlink/?tab=ldproxy) for both IBD and AD top variants (Figure 1C). This analysis uncovered twelve LD proxies that were common to both the IBD and AD lists of susceptibility loci (Supplementary Table S4), and they link back to rs17057051 in IBD and rs73223431 and rs28834970 in AD. Interestingly, rs17057051, rs73223431 and rs28834970 were all located in a single intron of Protein Tyrosine Kinase 2 Beta (*PTK2B*). *PTK2B* (also known as Pyk2) is an important intracellular kinase that contributes to diverse signaling pathways, including those involving MAP kinase and JNK. *PTK2B* has been reported to play a role in monocyte migration (30) and neutrophil degranulation (31), and it is well-known to be associated with risk of late onset AD (32) and to have an eQTL in monocytes (33). Moreover, Pyk2 has been identified as a key regulator of Interferon regulating factor 5 activation (an important IBD susceptibility gene), macrophage inflammatory response, and intestinal pathology (34).

Cell state specificity of IBD and AD

Both IBD and AD susceptibility loci have been reported to be enriched for genes expressed in peripheral monocytes (8, 35, 36), which are mostly recent bone marrow immigrants that are relatively undifferentiated. Myeloid cells adopt their final, functional states in tissue, in response to the local environment, and thus we assessed whether the microglial state of differentiation would yield differential enrichment for AD loci *vs.* the monocyte state. We therefore downloaded monocyte eQTL results (14) from EMBL-EBI eQTL catalogue (13) (https://www.ebi.ac.uk/eqtl/), and we used microglia eQTLs from our recent manuscript (16). In this study, we only kept the eSNP-eGene pairs with p-value<0.05, resulting in 10,215,002 monocyte eSNP-eGene pairs, and 263,263 microglia eSNP-eGene pairs. Integrating these results with the disease susceptibility results show that >60.5% of AD (23/38) lead SNPs and their LD proxies (664/920) are enriched among microglia eQTLs: permutation test, mean=2%, SD=2.05, p-value<1.00×10^{-4}. On the other hand, <12.9% of IBD (17/228) and IBD proxies (1,044/8,093) are also microglia eSNPs: permutation test, mean=2%, SD=0.83, p-value<1.00×10^{-4} (Figure 2A). Different from microglia, >70% of AD, AD proxies, IBD and IBD proxies were monocyte eSNPs: permutation test, AD: mean=30.8%, SD=7.52, IBD: mean=30.0%, SD=3.02, empirical p-value<1.00×10^{-4} (Figure 2A). Some of the difference in overlap with AD loci between the monocyte and microglial eQTLs is likely to be due to the parent studies given the smaller sample size and nuclear RNA-derived nature of the microglial data; both of these factors will tend to diminish the number of eQTL discovered.

We next compared the IBD eQTLs and AD eQTLs with GWAS results for six AD endophenotypes (i.e., amyloid, tangles, neuritic plaque burden, NFTs, cognitive decline and residual cognition adjusted by TDP pathology). Our results represented a high overlap between cognitive decline/NFTs/tangles and AD eQTLs in both microglia and monocyte, more than 18% of AD eQTLs in microglia and monocyte were also SNPs associated with cognitive decline, NFTs and tangles (two distinct measures of tau proteinopathy), while IBD eQTLs showed very few overlaps with AD endophenotypes (Figure 2C). Similar results were found in an analysis based on eGenes (Figure 2D), cognitive decline, NFTs and tangles showed a higher overlap percentage with AD eGenes in both microglia and monocyte than IBD. Interestingly, in microglia, we identified nine unique AD eGenes and five unique IBD eGenes associated with AD endophenotypes, while only *PTK2B* was shared between these two gene sets (Supplementary Table S5). In monocytes, we identified 44 unique AD eGenes and 186 unique IBD eGenes associated with AD endophenotypes (Supplementary Table S5), two genes were found shared between them: *PTK2B* and BCL2 Interacting Protein 3 Like (*BNIP3L*). *BNIP3L* has been reported to mitigate mitochondrial damage during intestinal inflammation, which is very important during IBD pathogenesis (37); it was also found to be reduced in AD patient samples (38).

By checking the genomic location of *PTK2B* in the human genome (GRCh38) on the UCSC genome browser (https://genome.ucsc.edu/), we found that other nearby genes were also reported to be associated with IBD and AD, for example, Clusterin (*CLU*) and Epoxide Hydrolase 2 (*EPHX2*). *CLU* is a multifunctional glycoprotein, which has been identified as a mediator of Aß toxicity (39). The overexpression of human *CLU* reduced the present of inflammatory cells and

cell death (40). *EPHX2* inhibition has been reported as a novel treatment for IBD (41), and the expression of *EPHX2* was higher in AD postmortem brain samples compared to control brain samples (42). Making this chromosome 8p21.2 locus a complex one with likely multiple independent associations to disease.

Genetic architecture of IBD and AD

We assessed the impact of the 228 genome-wide significant IBD risk loci on AD pathology by conducting an omnibus test, adjusting for age at death, sex and education, which evaluates the distribution of the associations with ten endophenotypes of AD (details can be seen in Figure 3 legend). We found that IBD showed a nominal significant effect on NFTs (p=0.013) (Figure 3A); that is, there is a small excess of association of IBD variants for a measure of taupathy.

Phenome-wide association studies (PheWAS) was further used to test the associations between 228 IBD variants (exposure) and ten AD endophenotypes (outcome) using R PheWAS package (18), adjusting for age at death, sex and education. We used a linear regression model giving the numeric phenotype outcomes. The result demonstrated that IBD showed a nominal significant negative effect on NFTs (beta=-1.04, p=0.013) (Figure 3B). Based on the analyses above, our results indicate that IBD variants may play a modest protective role on the accumulation of NFTs in the human brain regions.

Next, we used generalized summary statistics-based Mendelian randomization (GSMR) (19) and two-sample Mendelian randomization (2SMR) (20) to test causal effect of IBD (exposure, Ncases=12,882, Ncontrols=21,770), including UC and CD on AD (outcome, Ncases = 21,982;

Ncontrols= 41,944) of European descent. 200/228 variants were found shared between IBD summary statistics and AD summary statistics, filtered with SNP p-value less than 5×10^{-8}, Heidi outliner<=0.01, and LD<=0.05. Our results demonstrated that genetically determined IBD was significantly associated with a decreased risk of AD (GSMR: b_{xy}=-0.060, p-value=1.84×10^{-5}, Inverse variance-weighted (IVW): b_{xy}=-0.051, p-value=7.28×10^{-4}) (Figure 4A & D), subanalyses also showed an inversely causative relationship of UC (GSMR: b_{xy}=-0.033, p-value=0.009, IVW: b_{xy}=-0.045, p-value=0.02), and CD (GSMR: b_{xy}=-0.050, p-value=0.002, IVW: b_{xy}=-0.038, p-value=0.007), on AD, respectively (Figure 4B & C & E & F).

Genetic correlation between IBD and other traits

Finally, we used LD score regression (LDSC) (21) to estimate genetic correlations between IBD and AD, and other disease traits. To do this, we downloaded GWAS summary statistic from nine previously published studies, which were all found to be enriched for loci encoding myeloid genes. Including three IBD traits (IBD, UC and CD) (11), three neurodegenerative disorders (AD (12, 22), ALS (23) and Parkinson disease (PD) (24), another inflammatory disease (Multiple sclerosis, MS (25)), a metabolic disease, type 2 diabetes (T2D) (26) and three psychiatric disorders: bipolar disorder (BD) (27), major depressive disorder (MDD) (28) and schizophrenia (SCZ) (29). Genetic correlations for all 66 pairwise combinations of the eleven traits are shown in Figure 5. Adjusting for the number of traits tested, the FDR corrected *P*-value threshold (FDR<=0.05) was used to define significant genetic correlations. Based on LDSC analysis, we found IBD-related traits showed no significant genetic correlation with AD, ALS, PD and T2D, while they are positively correlated with MS (FDR<=0.014) (as expected, and previously reported (43)) and three psychiatric disorders (FDR<=0.013). AD, downloaded from two

independent studies, showed positive genetic correlation with ALS (FDR=0.013 and 0.016), BD (FDR=0.040) and T2D (FDR=0.048) in these analyses.

Discussion

This study systematically assessed the potential shared genetic architecture between IBD and AD, given that both sets of susceptibility loci display an enrichment for myeloid genes. Such shared architecture could significantly accelerate AD studies given the large number of IBD loci. However, we found that, overall, AD risk variants are mostly different from IBD risk variants and involve more functional consequences in the CNS-specific myeloid context of microglia (44). Microglia are the resident macrophages of the CNS, they play key roles in brain development and physiology during life and aging. By contrast, patients with IBD reportedly have peripheral "monocytosis", an excess of monocytes that has been proposed as a biomarker of severity in IBD (45). Microglia and monocytes are ontogenetically distinct: while they are both derived from the mesoderm, microglia derived from yolk-sac progenitors during embryogenesis (46), whereas monocytes continuously differentiate throughout postnatal life from bone marrow hematopoietic stem cells. Distinct developmental origin and renewal mechanisms imply that monocyte-derived macrophages and microglia-derived macrophages that infiltrate tissue, including the brain, may exert different functions in pathological processes.

We identified two genes that may be shared between IBD and AD: they are *PTK2B* and *BNIP3L*. Each has a different level of evidence. *PTK2B* encodes a cytoplasmic protein tyrosine kinase which is involved in calcium-induced regulation of ion channels and activation of the map kinase signaling pathway. It has been identified as a key regulator of interferon regulating factor 5

activation, macrophage inflammatory response, and intestinal pathology (34), and it is well-known to be associated with risk of late onset AD (32). *BNIP3L* was reported to mitigate mitochondrial damage during intestinal inflammation, which is very important during IBD pathogenesis (37), it was also found reduced in AD patient samples (38).

While an examination of individual susceptibility loci revealed little sharing between AD and IBD, our findings using more global approaches highlighted modest but intriguing evidence for a genetically protective effect of IBD susceptibility on AD, which is different from earlier reports (9, 10). Since the age of onset of IBD was generally younger than that of AD, patients with IBD were often treated with various medications before developing AD. Indeed, statistical data from previous studies showed that IBD was only significantly with elevated risk of AD in the 'mild' and 'moderate–severe' groups with drug treatment, but not in the 'surgery' group, suggesting that drug intervention might contribute greatly to AD risk in patients with IBD. Interestingly, the effect of greater IBD polygenic risk on diminishing NFT burden provides a potential mechanism for the effect of genetic predisposition to IBD on AD: that myeloid pathways involved in IBD also influence the accumulation of tau proteinopathy .

The genetic correlation of IBD with MS was consistent with previous reports, suggesting that our rigorously applied methodology produce robust, expected results in the correct directiuon of effect (47). Our results also showed significant positive genetic associations between IBD and psychiatric disorders (BD, SCZ and MDD). Psychiatric comorbidity, including depression, anxiety, bipolar disorder, and schizophrenia, is known to be more prevalent in IBD patients (48, 49). We also reported a positive genetic association between AD and ALS, while previous

studies reported no significant genetic correlation between AD and ALS (50). ALS is a sporadic or familial fatal neurodegenerative condition that affects motor neurons in primary motor cortex, brainstem and spinal cord. While predominantly a motor disorder, ALS is frequently associated with cognitive impairment, mostly of frontal type. The genetic link between AD and ALS may help advance the search for new therapies.

Conclusions

Our study provides a comprehensive genetic analysis between IBD and AD. We conclude that, overall, IBD risk variants are different from AD risk variants. AD risk variants are functionally distinct, being more significantly enriched in microglia eQTLs than IBD variants. Greater genetic risk for IBD has a negative impact on the accumulation of tau proteinopathy, prioritizing a set of IBD risk alleles among which there may be a protective effect in relation to AD. This is an intriguing observation that will require more extensive dissection of IBD's polygenic architecture to understand what aspect may help to reduce the accumulation of tau proteinopathy, which has been clearly implicated as a target of microglia in human AD (51, 52). This exercise integrating GWAS results with pertinent myeloid QTL data therefore offers an important insight that the many myeloid pathways implicated in IBD susceptibility should probably be deprioritized in relation to AD, focusing our attention on other pathways, particularly those that are more specific for the microglial context.

List of abbreviations

IBD: inflammatory bowel disease

CD: Crohn's disease

UC: ulcerative colitis

CNS: central nervous system

2SMR: 2-sample mendelian randomization

GSMR: generalized summary mendelian randomization

PheWAS: Phenome-wide association studies

ALS: amyotrophic lateral sclerosis

MS: multiple sclerosis

T2D: Type 2 diabetes

BD: bipolar disorder

MDD: major depressive disorder

SCZ: schizophrenia

PD: Parkinson's disease

LDSC: Linkage disequilibrium score regression

eQTL: expression quantitative trait locus

References

1. Weiskopf K, Schnorr PJ, Pang WW, Chao MP, Chhabra A, Seita J, et al. Myeloid Cell Origins, Differentiation, and Clinical Implications. Microbiol Spectr. 2016;4(5).
2. Alvarez-Errico D, Vento-Tormo R, Sieweke M, Ballestar E. Epigenetic control of myeloid cell differentiation, identity and function. Nat Rev Immunol. 2015;15(1):7-17.
3. Ramos GP, Papadakis KA. Mechanisms of Disease: Inflammatory Bowel Diseases. Mayo Clin Proc. 2019;94(1):155-65.
4. Muller PA, Matheis F, Mucida D. Gut macrophages: key players in intestinal immunity and tissue physiology. Curr Opin Immunol. 2020;62:54-61.
5. Gopinath A, Collins A, Khoshbouei H, Streit WJ. Microglia and Other Myeloid Cells in Central Nervous System Health and Disease. J Pharmacol Exp Ther. 2020;375(1):154-60.
6. Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer's disease. J Cell Biol. 2018;217(2):459-72.
7. Garre-Olmo J. [Epidemiology of Alzheimer's disease and other dementias]. Rev Neurol. 2018;66(11):377-86.

8. Raj T, Rothamel K, Mostafavi S, Ye C, Lee MN, Replogle JM, et al. Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science. 2014;344(6183):519-23.
9. Zingel R, Bohlken J, Kostev K. Association Between Inflammatory Bowel Disease and Dementia: A Retrospective Cohort Study. J Alzheimers Dis. 2021;80(4):1471-8.
10. Zhang B, Wang HE, Bai YM, Tsai SJ, Su TP, Chen TJ, et al. Inflammatory bowel disease is associated with higher dementia risk: a nationwide longitudinal study. Gut. 2021;70(1):85-91.
11. de Lange KM, Moutsianas L, Lee JC, Lamb CA, Luo Y, Kennedy NA, et al. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat Genet. 2017;49(2):256-61.
12. Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat Genet. 2019;51(3):414-30.
13. Kerimov N, Hayhurst JD, Peikova K, Manning JR, Walter P, Kolberg L, et al. A compendium of uniformly processed human gene expression and splicing quantitative trait loci. Nat Genet. 2021;53(9):1290-9.
14. Chen L, Ge B, Casale FP, Vasquez L, Kwan T, Garrido-Martin D, et al. Genetic Drivers of Epigenetic and Transcriptional Variation in Human Immune Cells. Cell. 2016;167(5):1398-414 e24.
15. Shabalin AA. Matrix eQTL: ultra fast eQTL analysis via large matrix operations. Bioinformatics. 2012;28(10):1353-8.
16. Fujita M, Gao Z, Zeng L, McCabe C, White CC, Ng B, et al. Cell-subtype specific effects of genetic variation in the aging and Alzheimer cortex. bioRxiv. 2022:2022.11.07.515446.
17. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559-75.
18. Carroll RJ, Bastarache L, Denny JC. R PheWAS: data analysis and plotting tools for phenome-wide association studies in the R environment. Bioinformatics. 2014;30(16):2375-6.
19. Zhu Z, Zheng Z, Zhang F, Wu Y, Trzaskowski M, Maier R, et al. Causal associations between risk factors and common diseases inferred from GWAS summary data. Nat Commun. 2018;9(1):224.
20. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018;7.
21. Bulik-Sullivan B, Finucane HK, Anttila V, Gusev A, Day FR, Loh PR, et al. An atlas of genetic correlations across human diseases and traits. Nat Genet. 2015;47(11):1236-41.
22. Wightman DP, Jansen IE, Savage JE, Shadrin AA, Bahrami S, Holland D, et al. A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. Nat Genet. 2021;53(9):1276-82.
23. van Rheenen W, van der Spek RAA, Bakker MK, van Vugt J, Hop PJ, Zwamborn RAJ, et al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat Genet. 2021;53(12):1636-48.
24. Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019;18(12):1091-102.

25. International Multiple Sclerosis Genetics C. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science. 2019;365(6460).
26. Spracklen CN, Horikoshi M, Kim YJ, Lin K, Bragg F, Moon S, et al. Identification of type 2 diabetes loci in 433,540 East Asian individuals. Nature. 2020;582(7811):240-5.
27. Mullins N, Forstner AJ, O'Connell KS, Coombes B, Coleman JRI, Qiao Z, et al. Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nat Genet. 2021;53(6):817-29.
28. Howard DM, Adams MJ, Clarke TK, Hafferty JD, Gibson J, Shirali M, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nat Neurosci. 2019;22(3):343-52.
29. Trubetskoy V, Pardinas AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature. 2022;604(7906):502-8.
30. Das P, Pal S, Oldfield CM, Thillai K, Bala S, Carnevale KA, et al. A PKCbeta-LYN-PYK2 Signaling Axis Is Critical for MCP-1-Dependent Migration and Adhesion of Monocytes. J Immunol. 2021;206(1):181-92.
31. Kamen LA, Schlessinger J, Lowell CA. Pyk2 is required for neutrophil degranulation and host defense responses to bacterial infection. J Immunol. 2011;186(3):1656-65.
32. Salazar SV, Cox TO, Lee S, Brody AH, Chyung AS, Haas LT, et al. Alzheimer's Disease Risk Factor Pyk2 Mediates Amyloid-beta-Induced Synaptic Dysfunction and Loss. J Neurosci. 2019;39(4):758-72.
33. Chan G, White CC, Winn PA, Cimpean M, Replogle JM, Glick LR, et al. CD33 modulates TREM2: convergence of Alzheimer loci. Nat Neurosci. 2015;18(11):1556-8.
34. Ryzhakov G, Almuttaqi H, Corbin AL, Berthold DL, Khoyratty T, Eames HL, et al. Defactinib inhibits PYK2 phosphorylation of IRF5 and reduces intestinal inflammation. Nat Commun. 2021;12(1):6702.
35. Novikova G, Kapoor M, Tcw J, Abud EM, Efthymiou AG, Chen SX, et al. Integration of Alzheimer's disease genetics and myeloid genomics identifies disease risk regulatory elements and genes. Nat Commun. 2021;12(1):1610.
36. Baillie JK, Arner E, Daub C, De Hoon M, Itoh M, Kawaji H, et al. Analysis of the human monocyte-derived macrophage transcriptome and response to lipopolysaccharide provides new insights into genetic aetiology of inflammatory bowel disease. PLoS Genet. 2017;13(3):e1006641.
37. Vincent G, Novak EA, Siow VS, Cunningham KE, Griffith BD, Comerford TE, et al. Nix-Mediated Mitophagy Modulates Mitochondrial Damage During Intestinal Inflammation. Antioxid Redox Signal. 2020;33(1):1-19.
38. Chakravorty A, Jetto CT, Manjithaya R. Dysfunctional Mitochondria and Mitophagy as Drivers of Alzheimer's Disease Pathogenesis. Front Aging Neurosci. 2019;11:311.
39. Foster EM, Dangla-Valls A, Lovestone S, Ribe EM, Buckley NJ. Clusterin in Alzheimer's Disease: Mechanisms, Genetics, and Lessons From Other Pathologies. Front Neurosci. 2019;13:164.
40. Wehrli P, Charnay Y, Vallet P, Zhu G, Harmony J, Aronow B, et al. Inhibition of post-ischemic brain injury by clusterin overexpression. Nat Med. 2001;7(9):977-9.
41. Reisdorf WC, Xie Q, Zeng X, Xie W, Rajpal N, Hoang B, et al. Preclinical evaluation of EPHX2 inhibition as a novel treatment for inflammatory bowel disease. PLoS One. 2019;14(4):e0215033.

42. Ghosh A, Comerota MM, Wan D, Chen F, Propson NE, Hwang SH, et al. An epoxide hydrolase inhibitor reduces neuroinflammation in a mouse model of Alzheimer's disease. Sci Transl Med. 2020;12(573).
43. Cotsapas C, Mitrovic M. Genome-wide association studies of multiple sclerosis. Clin Transl Immunology. 2018;7(6):e1018.
44. Hemonnot AL, Hua J, Ulmann L, Hirbec H. Microglia in Alzheimer Disease: Well-Known Targets and New Opportunities. Front Aging Neurosci. 2019;11:233.
45. Anderson A, Cherfane C, Click B, Ramos-Rivers C, Koutroubakis IE, Hashash JG, et al. Monocytosis Is a Biomarker of Severity in Inflammatory Bowel Disease: Analysis of a 6-Year Prospective Natural History Registry. Inflamm Bowel Dis. 2022;28(1):70-8.
46. Schulz C, Gomez Perdiguero E, Chorro L, Szabo-Rogers H, Cagnard N, Kierdorf K, et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science. 2012;336(6077):86-90.
47. Yang Y, Musco H, Simpson-Yap S, Zhu Z, Wang Y, Lin X, et al. Investigating the shared genetic architecture between multiple sclerosis and inflammatory bowel diseases. Nat Commun. 2021;12(1):5641.
48. Marrie RA, Walld R, Bolton JM, Sareen J, Walker JR, Patten SB, et al. Increased incidence of psychiatric disorders in immune-mediated inflammatory disease. J Psychosom Res. 2017;101:17-23.
49. Bernstein CN, Hitchon CA, Walld R, Bolton JM, Sareen J, Walker JR, et al. Increased Burden of Psychiatric Disorders in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019;25(2):360-8.
50. McLaughlin RL, Schijven D, van Rheenen W, van Eijk KR, O'Brien M, Kahn RS, et al. Genetic correlation between amyotrophic lateral sclerosis and schizophrenia. Nat Commun. 2017;8:14774.
51. Haage V, De Jager PL. Neuroimmune contributions to Alzheimer's disease: a focus on human data. Mol Psychiatry. 2022.
52. Patrick E, Olah M, Taga M, Klein HU, Xu J, White CC, et al. A cortical immune network map identifies distinct microglial transcriptional programs associated with beta-amyloid and Tau pathologies. Transl Psychiatry. 2021;11(1):50.

Acknowledgements

This study was supported by NIH grants (ROSMAP is supported by P30AG10161, P30AG72975, R01AG15819, R01AG17917, U01AG46152, U01AG61356; ROSMAP resources can be requested at https://www.radc.rush.edu).

Author information

Center for Translational and Computational Neuroimmunology, Department of Neurology and the Taub Institute for Research on Alzheimer's disease and the Aging brain, Columbia University Irving Medical Center, New York, NY, USA.

Lu Zeng, Charles C. White, Hans-Ulrich Klein, Philip L. De Jager

Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.

David A. Bennett

Contributions

LZ and PLD concept and designed the study; LZ performed the research; CCW provided data and code contributed to the analyses; HUK and DAB participated in the discussion and interpretation of the results; LZ and PLD wrote the paper; LZ created the figures which were edited by PLD; All the authors reviewed and revised the paper.

Corresponding author

Correspondence to Philip L. De Jager.

Ethics declarations

Competing interests

The authors declare no competing interests.

Figure legends



Figure 1. Overview of AD and IBD risk variants used in this study.

A) Manhattan plot of 38 genome-wide significant ($p<=5 \times 10^{-8}$) AD risk variants and 228 genome-wide significant ($p<=5 \times 10^{-8}$) IBD risk variants extracted from previous studies.

B, C) Venn diagram shows the number of SNPs that were unique to or shared between IBD, AD and their LD proxies ($R^2>=0.8$). LD proxies were calculated by using LDproxy (https://analysistools.cancer.gov/LDlink/?tab=ldproxy) with ±500MB base pair window.



Figure 2. Overlap between IBD/AD risk variants with microglia and monocyte

A) The percentage of IBD/AD risk variants overlapped with microglia or monocyte eQTLs.

$$\frac{No.of\ (SNP_i\ \cap eQTL_j)}{No.of\ SNP_i}$$

B) Genome browser shows the location of *PTK2B* in the hg38 and its nearby genes.

C) The percentage of IBD/AD eQTLs in microglia/monocyte overlapped with six AD endophenotypes.

$$\frac{No.of\ (eQTL_{ij}\ \cap\ AD\ endophenotypes\ SNP_m)}{No.of\ eQTL_{ij}}$$

D) The percentage of IBD/AD eGenes in microglia/monocyte overlapped with six AD endophenotypes.

$$\frac{eGenes\ \left(eQTL_{ij}\ \cap\ AD\ endophenotypes\ SNP_m\right)}{eGenes\ (eQTL_{ij})}$$

i denotes IBD, AD, IBD proxies or AD proxies; j represents microglia or monocyte; m represents six AD endophenotypes.



Figure 3. Genetic analysis between IBD and AD endophenotypes

A) The impact of IBD risk on AD endophenotypes (e.g. amyloid, plaque and tangles)**.** Each dot represents a ROSMAP AD endophenotype and its expected and observed associations with AD endophenotype. The expected P values assume a null distribution with no linear associations between IBD risk score and AD pathologies after adjusting age at death, sex and education. The gray and dark areas indicate the extreme ranges of the QQ plot as generated by chance at a threshold of *P*=0.05 and *P*=0.10, respectively. The 95 and 90% confidence intervals were empirically derived by randomly assigning participants with the IBD risk score and repeating the analysis 1,000 times. Based on the distribution of the observed *P* values for all the ten AD phenotypes. IBD risk score showed a nominal significant association with NFTs (omnibus *p*=0.0131, FDR=0.131).

B) Phenome-wide association plots of IBD risk with the ROSMAP AD endophenotypes. Each dot represents a ROSMAP AD endophenotypes, the red line is the p-value threshold (p≤0.05). The effect size denotes the beta value.



Figure 4. Scatter plots of MR analyses showing the causal effects of IBD on AD. Six different methods, including: Generalised Summary-data-based Mendelian Randomisation (GSMR), default inverse variance-weighted (IVW), weighted mode, weighted median, Mendelian randomization-Egger (MR-Egger) regression and simple median were used to evaluate the causal effects of IBD (UC and CD) on AD. The slope in each line represents the causal estimate of an exposure on corresponding outcome per method. (A, D) SNP's effect on IBD and AD; (B, E) SNP's effect on CD and AD; (C, F) SNP's effect on UC and AD.



Figure 5. Genetic correlation between neurological and inflammatory diseases

Genetic correlation estimates across 11 human diseases. The areas of the squares represent the absolute value of corresponding genetic correlations. After FDR correction at 5% significance level, genetic correlations estimate that are significantly different from zero are marked with an asterisk (* 0.01<FDR<=0.05; ** 0.001 <FDR<=0.01; *** FDR<=0.001). The blue color denotes a positive genetic correlation, the red color denotes a negative genetic correlation.